Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.49 |
| ▸ | QDPR | P09417 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.44 |
| ▸ | CDK9 | P50750 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521648 | 0.86 | CDK9 (0.47) | SUV39H2QDPRSIGMAR1CCNT1CDK9 | |
| SCHEMBL311532 | 0.84 | SIGMAR1 (0.48) | QDPRSIGMAR1ALDH1A1LMNASIRT6 | |
| SCHEMBL520056 | 0.84 | SUV39H2 (0.53) | SUV39H2QDPRSIGMAR1CCNT1CDK9 | |
| SCHEMBL310018 | 0.83 | SUV39H2 (0.47) | SUV39H2QDPRSIGMAR1ALDH1A1LMNA | |
| SCHEMBL310961 | 0.83 | ALDH1A1 (0.44) | QDPRSIGMAR1ALDH1A1LMNASIRT6 | |
| SCHEMBL2228095 | 0.83 | QDPR (0.57) | SUV39H2QDPRALDH1A1LMNASIRT6 | |
| SCHEMBL17197300 | 0.83 | QDPR (0.69) | SUV39H2QDPRCCNT1CDK9ALDH1A1 | |
| SCHEMBL2228100 | 0.83 | QDPR (0.57) | SUV39H2QDPRALDH1A1LMNASIRT6 | |
| SCHEMBL17197280 | 0.82 | QDPR (0.54) | QDPRALDH1A1LMNASIRT6KDM4E | |
| SCHEMBL12429007 | 0.82 | ALDH1A1 (0.43) | QDPRSIGMAR1ALDH1A1LMNASIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | SUV39H2 870/4885QDPR 807/4885SIGMAR1 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.